Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) FCF Margin: 2018-2025

Historic FCF Margin for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to -612.30%.

  • Bicycle Therapeutics' FCF Margin rose 89245.00% to -612.30% in Q3 2025 from the same period last year, while for Sep 2025 it was 4,216.68%, marking a year-over-year increase of 755769.00%. This contributed to the annual value of -13,829.92% for FY2024, which is 1263073.00% down from last year.
  • Per Bicycle Therapeutics' latest filing, its FCF Margin stood at -612.30% for Q3 2025, which was up 75.60% from -2,509.73% recorded in Q2 2025.
  • Bicycle Therapeutics' 5-year FCF Margin high stood at 497.32% for Q3 2021, and its period low was -2,509.73% during Q2 2025.
  • For the 3-year period, Bicycle Therapeutics' FCF Margin averaged around -642.01%, with its median value being -612.30% (2025).
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by 263,865bps in 2021, then spiked by 105,969bps in 2022.
  • Quarterly analysis of 5 years shows Bicycle Therapeutics' FCF Margin stood at -1,437.75% in 2021, then skyrocketed by 105,969bps to -378.06% in 2022, then spiked by 66,768bps to 289.62% in 2023, then plummeted by 25,747bps to 32.15% in 2024, then skyrocketed by 89,245bps to -612.30% in 2025.
  • Its FCF Margin was -612.30% in Q3 2025, compared to -2,509.73% in Q2 2025 and -871.75% in Q1 2025.